Chemistry:Veltuzumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD20 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6458H9918N1706O2026S46 |
| Molar mass | 145349.06 g·mol−1 |
  (what is this?) (verify) | |
Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] (As of December 2011), it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]
See also
- CD20 antagonist
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ↑ "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood 114 (18): 3864–71. October 2009. doi:10.1182/blood-2009-06-228890. PMID 19710501.
- ↑ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ↑ "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". British Journal of Haematology 169 (5): 701–10. June 2015. doi:10.1111/bjh.13354. PMID 25847298.
- ↑ "Harnessing Innate Immunity". Handbook of Therapeutic Antibodies (2nd ed.). John Wiley & Sons. 2014. p. 791. doi:10.1002/9783527682423.ch27. ISBN 978-3-527-68244-7. https://books.google.com/books?id=I9k8BAAAQBAJ&pg=PA791.
- ↑ 6.0 6.1 "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015. http://www.healio.com/hematology-oncology/hematology/news/online/%7B42042eb4-656d-4596-9853-896c755a2274%7D/fda-grants-orphan-drug-designation-to-veltuzumab-for-itp.
 |  |
